RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx (Nasdaq: RNXT) will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
CEO Shaun Bagai and CFO Mark Voll are scheduled to speak at 2:00 p.m. ET in New York. They plan to review third-quarter 2026 financial and business results, commercial execution, and factors driving physician adoption of the RenovoCath-enabled drug-delivery platform. A webcast replay will be available on the company’s website after the event.
RenovoRx (RNXT) will release its third quarter 2026 financial results and business highlights after market close on November 5, 2026. A conference call and webcast will follow at 4:30 p.m. ET. Management plans to discuss commercial execution and its view of the foundation for continued revenue growth and cash generation. It will also provide a clinical progress update focused on supporting physician adoption of its drug-delivery platform and expanding its use in additional solid tumor indications.
RenovoRx (RNXT) announced the first patient enrollment in PRISM-TAMP, a University of Vermont-sponsored trial studying pancreatic cancer treatment before surgery.
The investigator-initiated study evaluates gemcitabine delivered through Trans-Arterial Micro-Perfusion (TAMP), a platform for local drug delivery enabled by RenovoCath, in borderline resectable pancreatic ductal adenocarcinoma. This setting involves tumors near blood vessels that can make complete removal difficult. The study will assess tumor regression, surgical margins following treatment, and safety and tolerability. UVM plans to enroll approximately 10 patients; a second patient is progressing toward TAMP treatment. PRISM-TAMP is the first RenovoRx-supported investigator-initiated trial to reach enrollment. RenovoRx expects topline data from its separate Phase III TIGeR-PaC trial in the second half of 2027.
RenovoRx (RNXT) announced a peer-reviewed case series describing tumor treatment responses in two pancreatic cancer patients treated with its TAMP platform. Published in Case Reports in Oncology, the series involved patients with locally advanced pancreatic cancer whose tumors remained surgically unremovable because of complex blood vessel involvement despite extensive prior treatment.
Both received gemcitabine chemotherapy locally through an artery using RenovoCath, the device enabling TAMP, or Trans-Arterial Micro-Perfusion. Both showed reductions in CA 19-9, a marker used to monitor pancreatic cancer activity, and favorable imaging changes, including resolution of vascular narrowing. No major procedural complications were reported. Researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center authored the series.
RenovoRx (RNXT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026.
Management plans to review record second quarter 2026 revenue of $909,000 from RenovoCath sales, following approximately $1.1 million in 2025, driven by growing demand and repeat orders at high-volume cancer centers. The presentation will cover first commercial use of RenovoCath in a sarcoma patient and an update on the fully enrolled Phase III TIGeR-PaC trial of intra-arterial gemcitabine (IAG) in locally advanced pancreatic cancer, with trial completion expected in 1H 2027 and topline data in 2H 2027. Newly published PK-PD data showed TAMP delivery concentrated chemotherapy at the tumor site, locally extracting about 51% of the drug before it entered the bloodstream, with correlations suggesting improved tumor penetration and potential reduction in systemic exposure.
RenovoRx (Nasdaq: RNXT) reported peer‑reviewed PK/PD data from a sub‑study of its Phase III TIGeR‑PaC trial in Cancer Chemotherapy and Pharmacology, evaluating TAMP‑mediated intra‑arterial gemcitabine (IAG) versus standard intravenous gemcitabine (IVG) in 16 locally advanced pancreatic cancer patients.
The study showed an estimated ~51% local drug extraction at the tumor site and significantly reduced systemic gemcitabine exposure with IAG, alongside a statistically significant correlation between dFdU metabolite levels and reductions in CA 19‑9 tumor marker. RenovoRx achieved full TIGeR‑PaC enrollment in August 2026, targeting trial completion in 1H 2027 and topline data in 2H 2027, and reported approximately $1.1M RenovoCath sales in 2025 and record $909,000 revenue in Q2 2026. RenovoCath with gemcitabine and oxaliplatin has received multiple FDA Orphan Drug Designations.
RenovoRx (Nasdaq: RNXT) announced that Nasdaq has confirmed the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The closing bid price of its common stock met or exceeded $1.00 for 10 consecutive business days from August 6–19, 2026.
According to RenovoRx, the prior deficiency notice dated December 31, 2025 is now closed and RNXT continues trading on Nasdaq. Management highlighted recent record second-quarter revenue, growth in active commercial cancer center customers for RenovoCath, first commercial clinical use in a sarcoma patient, and completion of enrollment in the Phase III TIGeR-PaC trial.
RenovoRx (Nasdaq: RNXT) received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Application No. 18/184,620 covering methods and apparatuses for targeted therapeutic delivery for cancer using its RenovoCath® dual-occlusion catheter and TAMP™ platform. The patent, once issued, will expand protection for RenovoCath’s catheter system, including primary and secondary catheters, multiple ports, and expandable occlusion balloons that create a controlled treatment zone for localized drug delivery. With this allowance, RenovoRx’s global intellectual property portfolio totals 20 issued or allowed patents and 13 pending patents. The portfolio supports commercialization of RenovoCath, ongoing Phase III TIGeR-PaC clinical development of intra-arterial gemcitabine (IAG), and potential partnerships and licensing opportunities.
RenovoRx (Nasdaq: RNXT) reported record second quarter 2026 revenue of $909,000, up about 61% sequentially and 115% year over year, with gross margin around 84%. First-half 2026 revenue was about $1.5 million.
According to RenovoRx, active commercial cancer center customers reached 21, with a total commercial funnel of 63 centers. The company raised 2026 revenue guidance to $3.75–$4.25 million, implying approximately 241–286% growth versus 2025. Net loss for the quarter was about $2.9 million, or $0.06 per share, with cash and equivalents of roughly $9.5 million, which the company believes funds operations into the second half of 2027.
RenovoRx reported full enrollment of its Phase III TIGeR-PaC trial, expects completion in the first half of 2027 and topline data in the second half of 2027, and highlighted the first commercial RenovoCath use in sarcoma.
RenovoRx (Nasdaq: RNXT) announced full enrollment of its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, evaluating intra-arterial gemcitabine (IAG) delivered via the FDA-cleared RenovoCath device using the TAMP™ platform versus standard intravenous gemcitabine plus Abraxane. Patient enrollment closed as of August 7, 2026.
According to the company, the study’s primary endpoint is overall survival, with trial completion expected in the first half of 2027 after 86 events (patient deaths); 78 events had occurred as of August 11, 2026. Initial topline data are anticipated in the second half of 2027. The trial has passed two independent interim analyses (after the 26th event in 2023 and 52nd in 2025) with recommendations to continue. RenovoRx reported approximately $1.1 million in RenovoCath sales in 2025 and a record $563,000 in Q1 2026, and RenovoCath with gemcitabine has Orphan Drug Designation for pancreatic and bile duct cancer.